|
2025
|
Invention
|
Buprenorphine dosing regimens.
The disclosure provides a dosage regimen using sustained-release ... |
|
2024
|
G/S
|
Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and othe... |
|
|
Invention
|
Methods for administering buprenorphine.
The disclosure provides methods for administering bupre... |
|
|
Invention
|
Rapid induction with monthly injectable buprenorphine extended-release. The disclosure provides m... |
|
|
Invention
|
Rapid induction with monthly injectable buprenorphine extended-release.
The disclosure provides ... |
|
2023
|
Invention
|
Compositions, devices, and methods for the treatment of overdose and reward-based disorders.
Dru... |
|
|
Invention
|
Compositions, devices and methods for the treatment of alcohol use disorder.
Drug products adapt... |
|
|
G/S
|
Pharmaceutical preparations and substances in this class. Provision of pharmaceutical advice and ... |
|
|
G/S
|
Provision of health care advice; providing information relating to opioid dependence |
|
2022
|
G/S
|
Printed matter, namely, pamphlets, flyers, and brochures in the field of opioid and other substan... |
|
|
G/S
|
Printed matter, namely, information cards, leaflets and pamplets in the field of opioid and other... |
|
|
G/S
|
Printed matter in the field of opioid and other substance
use addiction, dependence, prevention,... |
|
|
Invention
|
Sustained delivery formulations of risperidone compound.
The present invention relates to a risp... |
|
|
Invention
|
Methods and compositions for treating cannabinoid overdose with a cannabinoid receptor antagonist... |
|
|
Invention
|
Syringe system. A medication component mixing system is formed of a first syringe, such as a fema... |
|
|
Invention
|
Compositions and methods for the treatment of opioid overdose. Drug products adapted for nasal de... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of substance
use disorders, substance dependence, ... |
|
2021
|
G/S
|
Pharmaceutical preparations; medicines for human and veterinary purposes; pharmaceutical preparat... |
|
|
Invention
|
Sustained delivery formulations of risperidone compound. The present invention relates to a rispe... |
|
|
Invention
|
Buprenorphine dosing regimens. The disclosure provides a dosage regimen using sustained-release b... |
|
|
G/S
|
Healthcare services, namely, addiction treatment services, providing emergency health information... |
|
2020
|
G/S
|
Healthcare; medical information; provision of medical information and advice via a website in the... |
|
|
G/S
|
Providing an interactive web site featuring technology that enables users to search, locate and a... |
|
|
Invention
|
Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions.
Dru... |
|
|
Invention
|
Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid recepto... |
|
|
Invention
|
Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor anta... |
|
|
Invention
|
Methods for treating schizophrenia.
The disclosure provides methods for treating negative, posit... |
|
|
Invention
|
Methods for treating schizophrenia. The disclosure provides methods for treating negative, positi... |
|
2019
|
Invention
|
Injectable flowable composition comprising buprenorphine. The present invention is directed to a ... |
|
|
Invention
|
Buprenorphine to treat respiratory depression.
The disclosure provides methods for treating, pre... |
|
|
Invention
|
Buprenorphine to treat respiratory depression. The disclosure provides methods for treating, prev... |
|
|
Invention
|
Sustained release small molecule drug formulation. min ratio of less than 200 and a lag time less... |
|
|
Invention
|
Sublingual and buccal film compositions. The present invention relates to products and methods fo... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of mental health diseases and disorders; Medicines ... |
|
|
Invention
|
Substituted 3,6-diazabicyclo[3.2.0]heptanes. The disclosure provides compounds having formula (I)... |
|
|
Invention
|
3 receptor antagonist compounds. The disclosure is directed to novel dopamine D3 receptor antagon... |
|
2018
|
Invention
|
Nasal drug products and methods of their use.
Drug products adapted for nasal delivery, comprisi... |
|
|
Invention
|
Intranasal naloxone compositions and methods of making and using same.
Disclosed herein are comp... |
|
|
Invention
|
Methods for treating schizophrenia.
The disclosure provides methods for treating psychiatric dis... |
|
|
Invention
|
Sustained-release buprenorphine solutions. The disclosure provides extended release pharmaceutica... |
|
|
Invention
|
Methods to treat opioid use disorder. The disclosure provides sustained-release buprenorphine for... |
|
|
Invention
|
Dopamine d3 receptor antagonists. The disclosure is directed to novel dopamine D3 receptor antago... |
|
2017
|
G/S
|
Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, s... |
|
|
Invention
|
Sustained-release buprenorphine formulations.
The disclosure is directed to sustained-release bu... |
|
|
G/S
|
Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatmen... |
|
|
G/S
|
Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment |
|
|
G/S
|
Providing temporary use of a web-based software application for accessing, operating, and using a... |
|
|
G/S
|
Provision of information and advice via a website in the field of opioid dependence and its treat... |
|
2016
|
Invention
|
Quantification of drugs in biological samples.
The disclosure provides methods for the detection... |
|
|
G/S
|
Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment an... |
|
|
Invention
|
Dopamine d3 receptor antagonists having a morpholine moiety. 3 receptors, such as treating substa... |
|
|
Invention
|
Psychiatric treatment for patients with gene polymorphisms.
The disclosure provides methods for ... |
|
|
Invention
|
Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine recept... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, ... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of mental health diseases and disorders; medicines ... |
|
|
G/S
|
Pharmaceutical and drug preparations for use in treatment of opioid overdose and addiction; medic... |
|
|
G/S
|
Pharmaceutical and drug preparations for use in treatment of opioid overdose and addiction; Medic... |
|
2015
|
Invention
|
Dopamine d3 receptor antagonist compounds. The disclosure is directed to novel dopamine D3 recept... |
